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Abstract
Background: Limited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma
(SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/
ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS).
Method: Members of the European–African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients un-
dergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics
were analysed with regard to RFS and OS.
Results: Among the 102 patients included from 24 European centres, 56 patients had anal cancer, and 46 patients had SCC from other
origin. RFS in patients with anal cancer and non-anal cancer was 16 and 9 months, respectively (P¼ 0.134). A positive resection mar-
gin significantly influenced RFS for both anal cancer and non-anal cancer liver metastases (hazard ratio 6.82, 95 per cent c.i. 2.40 to
19.35, for the entire cohort). Median survival duration and 5-year OS rate among patients with anal cancer and non-anal cancer were
50 months and 45 per cent and 21 months and 25 per cent, respectively. For the entire cohort, only non-radical resection was associ-
ated with worse overall survival (hazard ratio 3.21, 95 per cent c.i. 1.24 to 8.30).
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Conclusion: Liver resection/ablation of liver metastases from SCC can result in long-term survival. Survival was superior in
treated patients with liver metastases from anal versus non-anal cancer. A negative resection margin is paramount for accept-
able outcome.
Introduction
There is limited evidence to guide the management of patients
with liver metastases from squamous cell carcinoma (SCC). In
metastatic SCC, spread to the liver seems only possible through
systemic haematogenous dissemination, which explains the his-
torical concern that hepatectomy is less beneficial for these
patients. During the past two decades, several publications have
reported on liver resection for non-colorectal non-neuroendo-
crine liver metastases, unanimously concluding that it is a safe
treatment option with the potential of long-term survival1–5.
These studies have in common the limited number of patients
with SCC, and since the group of patients with non-colorectal
non-neuroendocrine liver metastases constitutes a highly hetero-
geneous group with regards to primary tumour location, histol-
ogy, biology, metastatic pathways, treatment strategies and
outcome, analysing factors influencing outcome in the subpopu-
lation with SCC liver metastasis is problematic.
The aim of this retrospective multicentre study was to de-
scribe patterns of disease recurrence after liver resection/abla-
tion of SCC liver metastases and factors associated with
recurrence-free survival (RFS) and overall survival (OS) through
collaboration within the European–African Hepato-Pancreato-
Biliary Association (E-AHPBA).
Methods
Members of the E-AHPBA were invited to include retrospectively
all consecutive patients submitted to liver resection and/or abla-
tion of histologically proven SCC liver metastases between 2002
and 2019. The study protocol was approved by the regional ethics
board in Stockholm, Sweden (Dnr 2019–04681). All participating
centres obtained ethical approval according to national/local leg-
islation before inclusion of patients. Participating centres entered
all data into a web-based application for collecting data,
Research Electronic Data Capture (REDCap, Stockholm, Sweden),
containing predefined case report forms designed specifically for
this project to collect relevant data.
The following data were recorded for each patient: age, sex,
ASA physical status, Eastern Cooperative Oncology Group (ECOG)
performance status and Charlson co-morbidity index6. Details
and treatment strategy of the primary tumour were collected
from medical records. The number, location and size of liver me-
tastases were recorded as well as chemotherapy strategy for met-
astatic disease and perioperative data concerning the liver
resection/thermal ablation. Any recurrence, site of recurrence
and potential re-treatments were recorded. Synchronous detec-
tion of liver metastases was defined as metastases diagnosed
within 3 months of primary tumour diagnosis. Radical resection,
R0, was defined as a 1-mm tumour-free margin. A positive resec-
tion margin was defined as R1. Complications were recorded up
to 30 days postoperatively and classified according to Clavien–
Dindo classification, where grades IIIb–IV were defined as a major
complication7. The patients were censored at date of last follow-
up. Analyses were performed for the entire group of included
patients and separately for patients with anal cancer liver metas-
tases.
Statistical analysis
Descriptive statistics were used to depict the study cohort.
Continuous variables were described as median (non-normally
distributed data) with range and differences tested with
Wilcoxon rank-sum test. Categorical variables were specified
with frequencies (percentage) and differences in proportions
were analysed with Pearson’s v2 test or Fisher’s exact test, the lat-
ter if sample sizes were small (10 patients or fewer). RFS was
measured from date of liver resection/ablation until date of first
recurrence, detected on any radiography, or death. Patients with
simultaneously diagnosed extrahepatic metastases that were not
treated with curative intent were excluded from the analysis of
RFS and factors influencing RFS. OS was measured from date of
liver resection/ablation until date of death or date of last follow-
up. Survival probabilities were illustrated using Kaplan–Meier
graphs and the log rank test for testing equality of survival func-
tions between groups. Patient and tumour factors potentially
influencing RFS and OS were analysed using Cox proportional
hazard regression model and included in the multivariable analy-
sis if P< 0.200 in the univariable analysis, and reported as hazard
ratio with associated 95 per cent confidence intervals. For the
purposes of data analysis in the regression models, values were
dichotomized based on median values. Statistical significance
was set at a two-sided alpha level of 0.050. All statistical analyses
were performed in STATA 15.0 (StataCorp, College Station, Texas,
USA).
Results
Some 102 patients were included from 24 European institutions;
80 of these patients were diagnosed and treated for liver metasta-
ses after 2010. There were 56 patients with anal cancer liver me-
tastases and 46 patients with non-anal SCC liver metastases. The
baseline patient and tumour characteristics are summarized in
Tables 1 and 2.
Chemotherapy was administered to 61 out of 102 patients;
details on regimen strategy and other perioperative characteris-
tics for the entire cohort are summarized in Table 2. A higher pro-
portion of patients with synchronous liver metastases (74 versus
52 per cent, P¼ 0.031) and multiple liver metastases (74 versus 50
per cent, P¼ 0.016) were treated with systemic chemotherapy
while primary tumour origin (anal versus non-anal, P¼ 0.540), ex-
trahepatic metastases (P¼ 0.811) and nodal status of primary
(P¼ 0.524) did not influence chemotherapy strategy. Response to
chemotherapy was reported for 37 of 61 patients: nine patients
had stable disease, 24 had partial response and four patients had
tumour progression.
Treatment with curative intent of simultaneously detected
extrahepatic metastases was given to 11 of 16 patients. The five
patients whose extrahepatic metastases eventually were not
treated with curative intent originated from anal cancer (1 patient),
cervical cancer (2 patients) and gallbladder cancer (2 patients).
Liver resection only was carried out in 87 patients, 10 patients
had a combination of resection and thermal ablation and five
patients underwent thermal ablation only. Median operative time
was 196 (range 40–580) minutes). Major complications occurred in
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nine patients within 30 days of surgery (Table 2). Median length of
hospital stay was 7 (range 0–87) days). Four patients died within
90 days of surgery of which one death was a direct consequence of
the surgical interventions (Clavien–Dindo V).
During a median follow-up time of 22 (range 0.5–145)
months from liver resection/ablation, recurrent liver metasta-
ses in the entire cohort were diagnosed in 42 patients. The me-
tastases were solely intrahepatic in 11 patients and intrahepatic
metastasis was associated with extrahepatic metastasis in 30
patients. Of those with any liver recurrence (42 patients), 15
patients had a second hepatectomy. A further 21 patients suffered
from extrahepatic recurrence only, including recurrence at pri-
mary tumour site, and none of them had surgery for these extra-
hepatic metastases or re-resection of primary site recurrences.
The extrahepatic recurrences (51 patients) were most often first di-
agnosed in the lung (24 patients), followed by distant lymph node
metastases (2 patients), peritoneum (6 patients), bone (5 patients),
brain (3 patients) and other (8 patients); extrahepatic recurrences
were in a single organ in 31 of 51 patients and were diagnosed at
multiple locations in the remaining 20 patients.
In the subgroup of patients with anal cancer liver metastases
(56 patients), 22 had intrahepatic recurrence after liver resection,
five had simultaneously diagnosed extrahepatic recurrence and a
further 11 patients later developed extrahepatic recurrence. Of
these 22 patients, 11 had a repeat liver resection of which nine
were considered to have curative intent.
The median RFS after liver resection in the entire cohort (exclud-
ing five patients whose simultaneous extrahepatic metastases were
Table 1 Clinicopathological characteristics in patients with liver metastases from squamous cell carcinoma
Anal cancer liver metastases (n¼56) Non-anal cancer liver metastases (n¼46)
Patient characteristics
Age (years)* 59 (29–81) 58 (37–82)
Gender, women 41 (73) 21 (46)
ASA class
1–2 44 (79) 30 (65)
3 9 (16) 13 (28)
Missing 3 (5) 3 (7)
ECOG performance status
0–1 45 (80) 27 (59)
2–3 6 (11) 13 (28)
Missing 5 (9) 6 (13)
BMI (kg/m2)* 25.9 (18.0–39.7) 23.9 (15.7–32.0)
CCI at diagnosis of liver metastases
6–8 32 (57) 21 (46)
9–13 18 (32) 24 (52)
Missing 6 (11) 1 (2)
Primary tumour
Origin
Head and neck NA 12 (26)
Lung NA 8 (18)
Oesophagus NA 7 (15)
Gallbladder NA 6 (13)
Cervix NA 6 (13)
Vagina NA 2 (4)
Prostate NA 1 (2)
Unknown/other NA 4 (9)
Stage of primary tumour
T1–T2 21 (38) 26 (57)
T3–T4 31 (55) 17 (37)
Missing 4 (7) 3 (6)
Nodal status of primary tumour
Negative 24 (43) 17 (37)
Positive 28 (50) 23 (50)
Missing 4 (7) 6 (13)
Liver metastases
Presentation
Synchronous 16 (29) 19 (41)
Metachronous 40 (71) 27 (59)
Number of liver metastases* 2 (1–10) 1 (1–4)
Size of largest liver metastasis (mm)* 31 (5–170) 34.5 (6–140)
Number of involved segments
1 16 (29) 18 (39)
2 or more 36 (64) 26 (57)
Missing 4 (7) 2 (4)
Distant metastases at diagnosis of liver
metastases, yes
Lung 7 (13) 9 (20)




Values in parentheses are percentages unless indicated otherwise; * values are median (range). ECOG, Eastern Cooperative Oncology Group; CCI, Charlson
co-morbidity index; NA, not applicable.
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not treated curatively and four patients with missing data on recur-
rence) was 11 (95 per cent c.i. 8 to 19) months, as outlined in Table 3.
In patients resected for liver-metastatic anal cancer, the median
RFS was 16 (95 per cent c.i. 8 to not reached) months and in the
non-anal cancer group the median RFS was 9 (95 per cent c.i. 7 to
18) months, log rank test P¼ 0.134 (Fig. 1a). The only factor signifi-
cantly influencing RFS among patients resected for liver-metastatic
anal cancer was a positive resection margin (hazard ratio 6.90, 95
Table 2 Treatment details in patients with liver metastases from squamous cell carcinoma
Anal cancer liver metastases
(n¼56)
Non-anal cancer liver metastases
(n¼46)
Treatment of primary tumour
Chemotherapy þ radiotherapy 46 (82) 9 (20)
Chemotherapy þ radiotherapy þ surgery 7 (12) 9 (20)
Radiotherapy 2 (4) 2 (4)
Radiotherapy þ surgery 1 (2) 4 (9)
Resection only 0 13 (28)
Resection þ chemotherapy 0 7 (15)
No treatment of primary tumour 0 2 (4)
Treatment of liver metastases
Surgery
Resection only 48 (86) 38 (83)
Resection þ thermal ablation 6 (11) 4 (9)
Thermal ablation only 2 (4) 3 (6)
Resection þ pancreaticoduodenectomy and hemicolectomy 0 1 (2)
Type of liver resection
Wedge 19 (35) 16 (37)
Segmentectomy 17 (31) 16 (37)
Hemihepatectomy 12 (22) 8 (19)
Trisectionectomy 3 (6) 1 (2)
Other 3 (6) 2 (5)
Surgical approach
Open 40 (74) 33 (77)
Laparoscopic 14 (26) 10 (23)
Complications according to Clavien–Dindo
Minor complications 19 (34) 28 (61)
Major complications 4 (7) 5 (11)
Resection margin of liver metastases
R0 47 (87) 37 (86)
R1 7 (13) 6 (14)
Systemic chemotherapy
None 21 (38) 20 (44)
Neoadjuvant 27 (48) 13 (28)
Adjuvant 7 (12) 11 (24)
Unspecified 1 (2) 2 (4)
Systemic chemotherapy regimen
5-fluorouracil þmitomycin 7 (20) 0
5-fluorouracil þ platinum-based 23 (66) 8 (31)
Platinum-based þ other 1 (3) 15 (58)
Other 4 (11) 3 (11)
Site of first recurrence after liver resection/ablation
None 23 (41) 14 (30)
Intrahepatic only 6 (10) 5 (11)
Extrahepatic only 11 (20) 10 (22)
Intra- and extrahepatic 16 (29) 14 (30)
Unknown 0 3 (7)
Values in parentheses are percentages
Table 3 Recurrence-free survival and overall survival in liver-metastatic squamous cell carcinoma
Recurrence-free survival Overall survival
No. of patients Median RFS
(months)
No. of patients Median survival
(months)
1-year OS rate (%) 3-year OS rate (%) 5-year OS rate (%)
Total cohort 93 11.1 (8.2–18.5) 102 36.7 (25.7–49.7) 85.0 50.7 36.3
Anal cancer 54 15.9 (8.0–NR) 56 49.7 (29.6–NR) 92.6 59.5 45.4
Non-anal SCC 39 8.7 (6.8–17.8) 46 20.9 (14.0–46.1) 75.2 39.2 25.0
Head and neck 12 8.7 (3.1–18.5) 12 23.2 (15.3–49.5) 90.9 40.9 13.6
Lung 8 4 (0.8–NR) 8 10.8 (2.2–NR) 41.7 20.8 20.8
Oesophageal 4 NR 7 20.9 (9.4–NR) 85.7 34.3 34.3
Gallbladder 4 5.8 (2.7–NR) 6 8.9 (1.5–NR) 50.0 33.3 33.3
Cervix 4 7.5 (6.8–NR) 6 17.7 (6.1–NR) 80.0 40.0 –
Values in parentheses are 95 per cent confidence intervals. RFS, recurrence-free survival; OS, overall survival; NR, not reached.
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per cent c.i. 2.33 to 20.50) (Table 4). Factors independently influenc-
ing RFS negatively in the entire cohort (93 patients) were an R1 re-
section (hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35) and non-
anal primary (hazard ratio 2.08, 95 per cent c.i. 1.10 to 3.96).
At the end of follow-up, 51 patients were still alive, resulting
in a median OS of 37 (95 per cent c.i. 26 to 50) months, with corre-
sponding 1-, 3-, and 5-year OS of 85, 51 and 36 per cent respec-
tively, for the entire cohort (Table 3). A favourable survival was
seen for liver-metastatic anal cancer with a median duration of
survival and 5-year OS rate of 50 (range 30 to not reached)
months and 46 per cent respectively, compared with 21 (range
14–46) months and 25 per cent respectively, in liver-metastatic
non-anal cancer, P¼ 0.006 (Fig. 1b). The median duration of sur-
vival and 5-year OS for men resected for anal cancer liver me-
tastases was 27 months and 25 per cent respectively, and the
corresponding survival data for women were 61 months and 53
per cent (P¼ 0.023). On multivariable analysis on factors
influencing survival among anal cancer liver metastases, no in-
dividual factor reached significance (Table 4). The only factor
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Fig. 1 Kaplan–Meier plots showing survival for patients with anal and non-anal squamous cell carcinoma liver metastases undergoing liver resection
or ablation
a Recurrence-free survival. b Overall survival. Survival for patients with anal cancer was superior to that of patients with non-anal cancer (P¼0.023)
Table 4 Uni- and multivariable analysis of prognostic factors for recurrence-free and overall survival in liver metastatic anal cancer
Recurrence-free survival Overall survival
Univariable Multivariable Cox regression analysis Univariable Multivariable Cox regression analysis
Variable P Hazard ratio P P Hazard ratio P
Patient charac-
teristics
Age 59 years 0.271 0.926
Male sex 0.429 0.029 3.00 (0.82–10.89) 0.096
ECOG score 2 0.545 0.798








0.231 0.105 1.04 (0.32–3.42) 0.938
Tumour stage
(T3/T4)



















R1 resection 0.010 6.90 (2.33–20.50) 0.001 0.025 1.62 (0.41–6.37) 0.498
Values in parentheses are 95 per cent confidence intervals. ECOG, Eastern Cooperative Oncology Group.
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cohort was a positive resection margin (hazard ratio 3.21, 95 per
cent c.i. 1.24 to 8.30). Excluding the ablated patients from the re-
gression analysis did not alter the result regarding the signifi-
cant impact of resection margin on RFS (hazard ratio 6.82, 95
per cent c.i. 2.40–19.35) or OS (hazard ratio 3.21, 95 per cent c.i.
1.24 to 8.30). Median duration of survival and OS rate for differ-
ent primary tumours origin of non-anal SCC are outlined in
Table 3.
Discussion
The present study includes the largest cohort to date of patients
undergoing liver resection for anal cancer liver metastases and
liver metastases from other SCC primaries. This study shows a
median OS of 37 months for patients with any SCC liver metas-
tases and a median OS of 50 months in the subgroup of anal
cancer liver metastases. Neither extrahepatic metastases, nor
synchronous detection of liver metastases, had a negative prog-
nostic impact on OS. A positive resection margin was found to
be associated with a more than three-fold increased risk of
death in the entire cohort, which emphasizes the importance of
achieving a negative resection margin and an important factor
to consider when selecting patients for liver resection of SCC
liver metastases.
As opposed to the well established practice of liver resection of
colorectal and neuroendocrine liver metastases, the benefit of liver
resection of SCC metastases and well defined selection criteria for
these patients are not fully established3,4,8–13. Historically, liver re-
section of SCC has been associated with a poorer outcome with
reported median OS following liver resection of 15 to
33 months1,2,9. Because of the relatively large number of patients
with anal cancer liver metastases included in the present study,
that group was analysed separately to gain further knowledge of
this disease with a known increasing incidence14. The liver is the
most frequent site of distant metastases in patients with anal SCC,
of which approximately 20 per cent develop liver metastases15. In
the present study, the median OS of 50 months and corresponding
5-year OS of 45 per cent compares favourably to other reports on
outcome of patients treated for liver-metastatic anal cancer,
reporting a median OS of between 22 and 53 months2,5,14,16,17.
In the present study, R1 resection was the only independent
negative prognostic factor after resection, yielding an almost
seven-fold increased risk of recurrence. In anal cancer, R1 resec-
tion was not an independent prognostic factor for OS. This could
potentially be explained by the high proportion of re-resections
performed, 11 out of 22 patients with recurrent liver metastases
were re-resected. In liver-metastatic anal cancer, the median OS
between men and women differed significantly, 27 months com-
pared with 61 months, to the benefit of women. Male sex is asso-
ciated with a poorer survival for most cancer sites, where anal
cancer is one of the cancer sites with the highest male-to-female
excess mortality ratio18. Unfortunately, the present study lacks
information on human papillomavirus prevalence and presence
of human immunodeficiency virus, making it difficult to explain
the observed differences.
In patients with liver-metastatic colorectal cancer, extrahe-
patic metastases are no longer considered a contraindication for
liver resection19. In the present study, a high proportion of
patients had extrahepatic metastases at time of liver resection.
Extrahepatic disease has been shown to be an independent prog-
nostic factor for reducing both RFS and OS in patients with non-
colorectal non-neuroendocrine liver metastases20. In the present
study, where extrahepatic metastases were treated with
potentially curative methods in most patients, no influence on ei-
ther RFS or OS was found.
Drawing any conclusions on survival outcomes of the cohort
of non-anal liver metastases is precarious, but, compared with
the limited cases in the existing literature, the small number of
each primary tumour site of this study might still contribute im-
portant information. Head and neck SCC is the sixth most com-
mon cancer worldwide and the liver is the third most common
site of metastasis with a reported median survival of about
4 months21–23. The median duration of survival of 23 months and
3-year OS rate of 41 per cent respectively, in the 12 patients with
head and neck SCC in the present study, compares favourably
with previously reported results of 18 months and 24 per cent re-
spectively1. Oesophageal cancer still represents an aggressive dis-
ease and optimal management of patients with liver
oligometastatic oesophageal cancer is still undefined24. Adam
and colleagues reported a 3-year OS rate of 32 per cent in patients
who underwent liver resection for liver metastases of oesopha-
geal cancer (both adenocarcinoma and SCC)1. It is to be compared
with the 5-year OS rate after liver resection in this study of 34 per
cent, potentially indicating a survival advantage in properly se-
lected patients.
Despite being the largest study of its kind, the present study is
still limited by the small number of included patients, clearly illus-
trated in the multivariable analysis with wide confidence intervals.
The study is also limited by its retrospective design and lack of
comparison group. Unfortunately, the present study lacks infor-
mation on human papillomavirus prevalence, presence of human
immunodeficiency virus and other immunosuppressive disorders.
The few patients included per centre obviously introduces a selec-
tion bias that cannot be controlled for. The patients in the present
series were treated over a period of almost 20 years and certainly
chemotherapy regimens, operative technique and diagnostic im-
aging modalities have changed substantially. In addition, the re-
sponse to chemotherapy was reported in only 60 per cent of
patients receiving preoperative chemotherapy, making it difficult
to analyse this factor which could have prognostic importance25.
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